Management of Gingival Smile using Botulinum Toxin Type A: pilot study

Faculdade de Odontologia da Universidade Federal do Rio Grande do Sul0 个研究点开始时间: 2020年3月11日最近更新: 2023年5月29日

试验速览

暂无简介。

•Patients aged between 18 and 40 years, who presented gingival exposure when smiling, greater than or equal to 3 mm, bilaterally.

•patients with systemic impairment, a history of hypersensitivity to the toxin, immunodeficiencies or who had applied the toxin less than six months ago; patients who received treatment with aminoglycosides, anticholinergic drugs or other agents that could interfere with neuromuscular transmissions or muscle relaxants (as the effect of botulinum toxin can be enhanced); patients with neuropathic diseases of the peripheral system, sclerosis or any disorders of the neuromuscular junction due to the increased risk of clinically significant adverse reactions; patients with infection at the application site, psychologically unstable or pregnant women.

发起方

Faculdade de Odontologia da Universidade Federal do Rio Grande do Sul